Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03773107 · OUTCOME

Objective Response Rate (ORR)

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)

What was measured

Objective response will be determined for each subject as a binary variable indicating whether or not the subject achieved a best overall response of PR or better as per the IMWG criteria

Analysis population: Participants who initiate protocol-directed therapy and have measurable disease at baseline.

Groups in this outcome

Phase I 5mg Ruxolitinib

Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 10 mg Ruxolitinib

Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Phase I 15 mg Ruxolitibin

Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I 5mg Ruxolitinib5
Phase I 10 mg Ruxolitinib4
Phase I 15 mg Ruxolitibin3

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase I 5mg Ruxolitinib0Not reportedNot reportedNot reportedNot reported
Phase I 10 mg Ruxolitinib2Not reportedNot reportedNot reportedNot reported
Phase I 15 mg Ruxolitibin1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      3
    units
    Participants
description
Objective response will be determined for each subject as a binary variable indicating whether or not the subject achieved a best overall response of PR or better as per the IMWG criteria
groups
  1. description
    Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG000
    title
    Phase I 5mg Ruxolitinib
  2. description
    Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG001
    title
    Phase I 10 mg Ruxolitinib
  3. description
    Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid
    id
    OG002
    title
    Phase I 15 mg Ruxolitibin
param Type
NUMBER
population Description
Participants who initiate protocol-directed therapy and have measurable disease at baseline.
reporting Status
POSTED
time Frame
Approximately 180 days after treatment start (disease assessment occurred after every 28-day cycle)
title
Objective Response Rate (ORR)
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice